FindTrial
Sign In

nab-paclitaxel + gemcitabine

DRUG6 trials

Sponsors

Institut Paoli-Calmettes, TG Therapeutics, Inc., Chinese PLA General Hospital, RenJi Hospital, Dartmouth-Hitchcock Medical Center

Conditions

Colorectal CancerEsophageal CancerFirst-lineGastric CancerGastrointestinal Stromal Tumor (GIST)Metastatic Pancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaPancreas Adenocarcinoma

Phase 1

Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer
CompletedNCT02174887
Institut Paoli-CalmettesPancreatic Adenocarcinoma
Start: 2014-09-30End: 2016-10-31Updated: 2017-03-28
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
CompletedNCT02574663
TG Therapeutics, Inc.Colorectal Cancer, Esophageal Cancer, Gastric Cancer +3
Start: 2015-09-11End: 2018-08-31Updated: 2019-10-02
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
RecruitingNCT05218889
Chinese PLA General HospitalPancreas Cancer, Pancreatic Cancer, Pancreatic Neoplasms +1
Start: 2021-08-04End: 2025-06-30Target: 90Updated: 2024-12-31
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
RecruitingNCT07377045
Oncomatryx Biopharma S.L.Pancreatic Adenocarcinoma Metastatic
Start: 2025-10-28End: 2029-03-01Target: 69Updated: 2026-01-29

Phase 2

Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
Not yet recruitingNCT06621095
RenJi HospitalFirst-line, Metastatic Pancreatic Cancer, Pancreatic Cancer
Start: 2024-10-30End: 2026-12-31Target: 104Updated: 2024-10-01
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
RecruitingNCT07043270
Dartmouth-Hitchcock Medical CenterPancreas Adenocarcinoma
Start: 2025-09-29End: 2029-07-01Target: 35Updated: 2025-10-20

Related Papers

Preliminary results of ALTER-PA-001 trial: A multicenter, open-label, randomized, phase II trial of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer.
Journal of Clinical Oncology2026-01-10
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study.
2025-10-13
First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.
Journal of Clinical Oncology2025-05-281 citations
ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer.
Journal of Clinical Oncology2025-05-28
Abstract 6824: Efficacy and mechanism of surufatinib combination with PD-1 monoclonal antibody and chemotherapy for the treatment of pancreatic cancer with liver metastasis in animal models
Cancer Research2025-04-21
Abstract 2129: Efficacy and underlying mechanisms of surufatinib combined with PD-1 monoclonal antibody and chemotherapy in pancreatic cancer
Cancer Research2024-03-22
Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
Journal of Clinical Oncology2024-01-202 citations
A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
Journal of Clinical Oncology2023-06-015 citations